Incidence and prognostic value of malnutrition and wasting in human immunodeficiency virus-infected outpatients
Article Abstract:
Malnutrition may be an important predictor of survival in AIDS patients. Researchers studied 100 HIV-infected patients and found that 63% showed signs of malnutrition. Decreasing body cell mass (BCM) was the main indicator of malnutrition in HIV patients, and was independent of CD4+ cell counts. Patients showed evidence of malnutrition before symptoms of HIV disease were apparent. Low levels of certain blood proteins, along with decreased BCM, predicted decreased survival of AIDS patients. Other studies have found that the risk of malnutrition increases as the disease progresses, even though caloric intake remains relatively constant. Evidence of malnutrition should be included in classifications of disease severity and outcome among HIV-infected patients.
Publication Name: Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology
Subject: Health
ISSN: 1077-9450
Year: 1995
User Contributions:
Comment about this article or add new information about this topic:
Oxandrolone, used for treatment of wasting disease in HIV-1 infected patients, does not diminish the antiviral activity of deoxynucleoside analogues in pymphocyte and macrophage cell cultures
Article Abstract:
Oxandrolone can be safely used to counter the effects of Wasting Syndrome in HIV-1 infected patients without interfering with or diminishing the effects of ZDV, ddI, or ddC. Oxandrolone is an anabolic steroid used to promote weight gain, especially lean body mass weight gain. Even though antivirals such as ZDV are the primary therapy used to fight the HIV-1 progress, other therapies are needed to deal with corollary and incidental physical problems, such as Wasting Syndrome.
Publication Name: Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology
Subject: Health
ISSN: 1077-9450
Year: 1999
User Contributions:
Comment about this article or add new information about this topic:
Short-term effects of large-dose vitamin A supplementation on viral load and immune response in HIV-infected women
Article Abstract:
Large doses of vitamin A appear to have no effect on HIV. Researchers randomly assigned 40 HIV-positive women to take a single dose of 300,000 IU of vitamin A or a placebo. None of women who took vitamin A developed any adverse effects from the vitamin. The vitamin did not reduce viral blood levels or increase T cell counts compared to placebo.
Publication Name: Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology
Subject: Health
ISSN: 1077-9450
Year: 1999
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Host-directed and immune-based therapies for human immunodeficiency virus infection. Does marijuana affect viral loads in people with HIV?
- Abstracts: Infection of baboons with simian human immunodeficiency viruses. Pathologic and serologic responses of isogeneic twin lambs to phenotypically distinct lentiviruses
- Abstracts: Disseminated Mycobacterium avium infection among HIV-infected patients in Kenya. Mycobacterial infection in Mexican AIDS patients
- Abstracts: Changes in membrane enzymes and glycosphingolipids in lymphocytes from HIV-1-infected and noninfected intravenous drug users
- Abstracts: Prevalence, incidence, and risks for HIV-1 infection in female sex workers in Miami, Florida. HIV prevalence and sexual behavior in a cohort of New York City gay men (aged 18-24)